Lipocine Inc. (LPCN)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenues | 622,849 | - | 89,565 | |
| Research and development | 2,136,769 | 1,585,233 | 1,874,721 | |
| General and administrative | 890,433 | 1,045,240 | 1,507,412 | |
| Total operating expenses | 3,027,202 | 2,630,473 | 3,382,133 | |
| Operating loss | -2,404,353 | -2,630,473 | -3,292,568 | |
| Unrealized loss on warrant liability | - | 138,081 | -84,430 | |
| Interest and investment income | 198,637 | 273,574 | 308,845 | |
| Total other income | 198,637 | 411,655 | 224,415 | |
| Income (loss) before income tax expense | -2,205,716 | -2,218,818 | -3,068,153 | |
| Income tax expense | - | - | 481 | |
| Net income (loss) | - | -2,218,818 | -3,068,634 | |
| Net loss attributable to common shareholders net income (loss) attributable to common shareholders | -2,205,716 | -2,218,818 | -3,068,634 | |
| Basic earnings (loss) per share attributable to common stock | -0.41 | -0.41 | -0.57 | |
| Diluted earnings (loss) per share attributable to common stock | -0.41 | -0.44 | -0.56 | |
| Weighted average common shares outstanding, basic | 5,351,957 | 5,347,940 | 5,343,922 | |
| Weighted average common shares outstanding, diluted | 5,351,957 | 5,347,940 | 5,343,922 | |